Back to the main directory
Company Analysis / Equity
- CTSO: $1.5M Ph2 NHLBI Grant for HemoDefend by Zacks
- CTSO: Clinical Outcomes Data Continues To Drive Strong Revenue Growth by Zacks
- CTSO: Data Registry, Other Developments Bode Well for Increased Adoption by Zacks
- CTSO: FDA Requests Add l Info for EAP Designation by Zacks
- CTSO: Product Sales Rebounding w/ Sales Force Rebuilding, Add l Distribution by Zacks
- CTSO: Q1 Inline. Continue To Expect Accelerating Growth in 2H by Zacks
- CTSO: Record Product Sales, Again. Data Supports Cardiac Surgery by Zacks
- CTSO: Record Product Sales, Readying for Uplisting by Zacks
- CTSO: Record Product Sales and Total Sales. Potential New Indication in MERS by Zacks
- CTSO: Reorders Fuel Record Product Sales. New Territories Coming Online Will Complement This by Zacks
- CTSO: Strong Recovery in Product Sales Following Sales Force Restructuring by Zacks
- CTSO: Product Sales Very Strong, Well Ahead of Our Estimate by Zacks
- Business Update Call, Dosing Study Details by Zacks
- CTSO: FDA Approves U.S. Study by Zacks
- CYRX: 10 Straight Quarters of Sequential Revenue Growth by Zacks
- CYRX: Big Downward Revision To Guidance. Sales Delayed , Not Lost by Zacks
- CYRX: Customer Wins, Ramping Utilization Could See 2016 Dwarf 48% Growth of 2015 by Zacks
- CYRX: Operational Update. Shares Have More Room to Run by Zacks
- CYRX: Q2 A New Revenue Record Although Softer Than Expected. But Revenue Guidance of 150%+ Reiterated. by Zacks
- CYRX: Revenue Guidance of +150% - 200%! by Zacks
- CYRX: Very Solid Quarter. Growing More Confident of Nearing Inflection by Zacks
- Revenue Streak Continues, Positive Gross Profit by Zacks
- Initiating Coverage by Zacks
- Progress on Product Sales, Gov't Contracts, Commercialization Plan by Zacks
- Q2 Results / Operational Plan Moving Forward by Zacks